Compare DexCom, Inc. (DXCM) vs Home Depot Inc (HD) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Home Depot (HD) trades at $346.25, up 2.52% today, with a bullish technical signal and strong institutional support. The stock shows mixed earnings performance with recent beats but faces margin compression as net income margin declined from 10.87% in 2022 to 8.41% in 2026. Valuation metrics include P/E of 24.25 and P/S of 2.04, while analyst consensus targets $370.59 with 59% buy ratings. Recent dividend of $2.33 per share reinforces shareholder returns amid challenging housing market conditions.

HD maintains solid fundamentals with $159.5B revenue and robust cash flow generation, though margin pressures and housing market sensitivity present headwinds. The stock offers value near current levels with analyst upside potential, but requires monitoring of Pro segment performance and interest rate impacts on home improvement spending for sustained growth.